Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin in the treatment of lupus nephritis

This article was originally published here

The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclinical Module and

The post Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin in the treatment of lupus nephritis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply